StrideBio Funding: $82M Raised, Series B (2021)

StrideBio funding overview

StrideBio is based in Durham. StrideBio has raised $82M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in March 2021. The round record for StrideBio runs through 2021; nothing later has been disclosed. Investors on record include Northpond Ventures, Novo Holdings A/S, Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and 5 others. 11 distinct backers are named across the disclosed rounds.

StrideBio at a glance

Total raised: $82M
Latest round: Series B
Latest round date: March 2021
Headquarters: Durham
Notable investors: Northpond Ventures, Novo Holdings A/S, Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital, UF Innovate Ventures, Hatteras Venture Partners

Frequently asked about StrideBio funding

How much has StrideBio raised?: StrideBio has raised $82M in total disclosed funding across the rounds on record.
Who has invested in StrideBio?: Northpond Ventures, Novo Holdings A/S, Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital are named among the investors backing StrideBio.
What was the latest StrideBio funding round?: The most recent disclosed round is a Series B, announced in March 2021.
Where is StrideBio based?: StrideBio is based in Durham.
When did StrideBio last raise?: The last disclosed StrideBio round closed in March 2021 at Series B.

StrideBio totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Durham below to benchmark round size and investor mix.

StrideBio Funding: $82M Raised, Series B (2021)

StrideBio funding overview

StrideBio at a glance

Frequently asked about StrideBio funding

Companies related to StrideBio (36)

Browse related funding lists (7)